[97] S. Tsiligiannis, B. C. Wick-Urban, J. van der Stam, and J. C. Stevenson, “Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms,” Maturitas, vol. 139, pp. 20–26, Sep. 2020, doi: 10.1016/j.maturitas.2020.05.002.
[98] D. F. Archer, J. H. Pickar, D. C. MacAllister, and M. P. Warren, “Transdermal estradiol gel for the treatment of symptomatic postmenopausal women,” Menopause, vol. 19, no. 6, pp. 622–629, 2012, doi: 10.1097/gme.0b013e31823b8867.
[99] Y. Vinogradova, C. Coupland, and J. Hippisley-Cox, “Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.,” BMJ, vol. 364, p. k4810, Jan. 2019, doi: 10.1136/bmj.k4810.
[100] M. Canonico et al., “Postmenopausal hormone therapy and risk of stroke: Impact of the route of estrogen administration and type of progestogen,” Stroke, vol. 47, no. 7, pp. 1734–1741, 2016, doi: 10.1161/STROKEAHA.116.013052.
[101] M. Canonico, “Hormone therapy and risk of venous thromboembolism among postmenopausal women.,” Maturitas, vol. 82, no. 3, pp. 304–307, Nov. 2015, doi: 10.1016/j.maturitas.2015.06.040.
[102] M. R. Rizzo, S. Leo, P. De Franciscis, N. Colacurci, and G. Paolisso, “Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome,” Age (Omaha)., vol. 36, no. 1, pp. 265–274, 2014, doi: 10.1007/s11357-013-9554-7.
[103] W. B. White, V. Hanes, M. Mallareddy, and V. Chauhan, “Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension.,” J. Am. Soc. Hypertens., vol. 2, no. 1, pp. 20–27, 2008, doi: 10.1016/j.jash.2007.08.004.
[104] A. Fournier, F. Berrino, and F. Clavel-Chapelon, “Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.,” Breast Cancer Res. Treat., vol. 107, no. 1, pp. 103–111, Jan. 2008, doi: 10.1007/s10549-007-9523-x.
[105] Y. Vinogradova, C. Coupland, and J. Hippisley-Cox, “Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.,” BMJ, vol. 371, p. m3873, Oct. 2020, doi: 10.1136/bmj.m3873.
[106] H. Lyytinen, E. Pukkala, and O. Ylikorkala, “Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.,” Obstet. Gynecol., vol. 113, no. 1, pp. 65–73, Jan. 2009, doi: 10.1097/AOG.0b013e31818e8cd6.
[107] P.-Y. Scarabin, E. Oger, G. Plu-Bureau, and EStrogen and THromboEmbolism Risk Study Group, “Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.,” Lancet (London, England), vol. 362, no. 9382, pp. 428–32, Aug. 2003, doi: 10.1016/S0140-6736(03)14066-4.
[108] M. Canonico et al., “Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.,” Circulation, vol. 115, no. 7, pp. 840–5, Feb. 2007, doi: 10.1161/CIRCULATIONAHA.106.642280.
[109] M. Canonico et al., “Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.,” Arterioscler. Thromb. Vasc. Biol., vol. 30, no. 2, pp. 340–5, Feb. 2010, doi: 10.1161/ATVBAHA.109.196022.
[110] M. Š. Goldštajn et al., “Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review,” Arch. Gynecol. Obstet., vol. 307, no. 6, pp. 1727–1745, Jun. 2022, doi: 10.1007/s00404-022-06647-5.
[111] C. Schneider, S. S. Jick, and C. R. Meier, “Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations,” Climacteric, vol. 12, no. 5, pp. 445–453, Jan. 2009, doi: 10.1080/13697130902780853.
[112] J. Dinger, K. Bardenheuer, and K. Heinemann, “Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women,” Climacteric, vol. 19, no. 4, pp. 349–356, Jul. 2016, doi: 10.1080/13697137.2016.1183624.
[113] V. Beral, K. Gaitskell, C. Hermon, K. Moser, G. Reeves, and R. Peto, “Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.,” Lancet (London, England), vol. 385, no. 9980, pp. 1835–1842, May 2015, doi: 10.1016/S0140-6736(14)61687-1.
[114] C. Castelo-Branco et al., “Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation,” Menopause, vol. 6, no. 4, pp. 307–311, 1999, doi: 10.1097/00042192-199906040-00006.
[115] Л.А. Ашрафян, В.Е. Балан, И.И. Баранов, Ж.Е. Белая, С.А. Бобров, А.В. Воронцова, С.О. Дубровина, И.Е. Зазерская, И.А. Иловайская, Л.Ю. Карахалис, О.М. Лесняк, М.И. Мазитова, Н.М. Подзолкова, А.Э. Протасова, В.Н. Серов, А.А. Сметник, Л.С. Сотникова, Е.А. Ульрих, Г.Е. Чернуха, С.В. Юренева. Совместная позиция экспертов РОАГ, РАМ, АГЭ, РАОП / под ред. В.Н. Серова и С.В. Юреневой, “Алгоритмы применения менопаузальной гормональной терапии у женщин в период пери- и постменопаузы.,” Акушерство и гинекология., vol. 3: 210–221, 2021, doi: https://dx.doi.org/10.18565/aig.2021.3.210-221.
[116] P. Stute, J. Neulen, and L. Wildt, “The impact of micronized progesterone on the endometrium: a systematic review.,” Climacteric, vol. 19, no. 4, pp. 316–328, Aug. 2016, doi: 10.1080/13697137.2016.1187123.
[117] M. Bińkowska and J. Woroń, “Progestogens in menopausal hormone therapy.,” Prz. menopauzalny = Menopause Rev., vol. 14, no. 2, pp. 134–143, Jun. 2015, doi: 10.5114/pm.2015.52154.